Pages that link to "Q33598446"

The following pages link to Olanzapine: a basic science update. (Q33598446):

Displaying 19 items.

• Efficacy and tolerability of pharmacotherapy options for the treatment of irritability in autistic children (Q24564288) (← links)
• Pharmacological Stimulation of Locus Coeruleus Reveals a New Antipsychotic-Responsive Pathway for Deficient Sensorimotor Gating (Q30466233) (← links)
• Olanzapine: an updated review of its use in the management of schizophrenia (Q32058541) (← links)
• Cheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting (Q33866119) (← links)
• Olanzapine in the treatment of schizophrenia : an open label comparative clinical trial from north India (Q34205865) (← links)
• Olanzapine: a review of its use in the treatment of bipolar I disorder (Q34432134) (← links)
• Determination of olanzapine and N-desmethyl-olanzapine in plasma using a reversed-phase HPLC coupled with coulochemical detection: correlation of olanzapine or N-desmethyl-olanzapine concentration with metabolic parameters (Q34761472) (← links)
• The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics (Q35370032) (← links)
• Clinical pharmacology of atypical antipsychotics: an update. (Q35728228) (← links)
• Olanzapine Attenuates Mechanical Allodynia in a Rat Model of Partial Sciatic Nerve Ligation (Q35847279) (← links)
• Typical and atypical antipsychotic drugs increase extracellular histamine levels in the rat medial prefrontal cortex: contribution of histamine h(1) receptor blockade (Q35966817) (← links)
• Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy (Q36070497) (← links)
• Neuroanatomical substrates of the disruptive effect of olanzapine on rat maternal behavior as revealed by c-Fos immunoreactivity (Q36389076) (← links)
• Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response (Q36804367) (← links)
• The SWITCH study: rationale and design of the trial. (Q38979325) (← links)
• Clozapine-induced ERK1 and ERK2 signaling in prefrontal cortex is mediated by the EGF receptor. (Q46092553) (← links)
• Clozapine decreases [3H] CP 58630 binding to the cannabinoid 1 receptor in the rat nucleus accumbens. (Q46581750) (← links)
• Lower phosphorylated glycogen synthase kinase-3B levels in platelets of patients with schizophrenia: increment by olanzapine treatment. (Q54352444) (← links)
• Clinical Pharmacokinetics of Atypical Antipsychotics: An Update (Q89145780) (← links)